GlassScriptPhysician profile
Gaurav Narayan Mathur
NPI 1588152367
$540.75
in general payments reported to CMS, 2019-2025
10 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Addiction Medicine (Internal Medicine) provider received nationally (typical 2025 total: $124).
See the full distribution for Addiction Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.29 · 2020: $144 · 2022: $24.21 · 2023: $29.24 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $302.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $128.63 | 2019-2020 | |
| Depuy Synthes Sales INC. | $117.65 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $93.72 | 2025 | Airsupra |
| Janssen Pharmaceuticals, INC | $42.53 | 2019-2020 | |
| Alkermes, INC. | $29.95 | 2025 | Vivitrol |
| Actelion Pharmaceuticals US, INC. | $29.24 | 2023 | Uptravi, Opsumit |
| Ucb, INC. | $27.16 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.83 | 2019-2025 | Lifevest |
| Abbott Laboratories | $24.21 | 2022 | |
| Braeburn INC. | $21.83 | 2025 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gaurav Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.